Laboratory Diagnosis of Creutzfeldt-Jakob Disease
NEJM 386:1345-1350, Zerr, I., 2022
Clinicopathologic conference, Frontotemporal Lobar Degeneration with tau-positive inclusions consistent with Picks disease
NEJM 383:2666-2675, Case 41-2020, 2020
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Clinicopathologic Conference, Creutzfeldt-Jakob Disease
NEJM 381:1569-1578, Case 32-2019, 2019
Atypical Parkinsonian Syndromes: A General Neurologists Perspective
Eur J Neurol 25:41-58, Deutschlander, A.B.,et al, 2018
Characteristics in Limbic Encephalitis with Anti-Adenylate Kinase 5 Autoantibodies
Neurol 88:514-524,508, Do, L. & Chanson, E., 2017
A 64-year-old Man with Visual Distortions
Neurol 87:e252-e256, McGrath, E.R.,et al, 2016
Clinicopathologic Conference, Frontotemporal Lobar Degeneration with Tau-positive Inclusions (Picks Disease Subtype) Due to a Gly389Arg MAPT Mutation, Resulting in the Behavioral Variant of Frontotemporal Dementia with Parkinsonism
NEJM 372:1151-1162, Miller, B.L.,et al, 2015
Criteria for the Diagnosis of Corticobasal Degeneration
Neurol 80:496-503, Armstrong, M.J.,et al, 2013
A Comparison of Tau and 14-3-3 Protein in the Diagosis of Creutzfeldt-Jakob Disease
Neurol 79:547-552, Hamlin, C.,et al, 2012
Tau Forms in CSF as a Reliable Biomarker for Progressive Supranuclear Palsy
Neurol 71:1796-1803, Borroni,B.,et al, 2008
Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia
Arch Neurol 63:144-146,146, Rikkert,M.G.M.O.,et al, 2006
Frontotemporal Dementia: Clinicopathological Correlations
Ann Neurol 59:952-962, Forman,M.S.,et al, 2006
CSF Tests in the Differential Diagnosis of Cretuzfeldt-Jakob Disease
Neurol 67:637-643, Sanchez-Juan,P.,et al, 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Tau Protein and 14-3-3 Protein in the Differential Diagnosis of Creutzfeldt-Jakob Disease
Neurol 58:192-197, Otto,M.,et al, 2002
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Use of 14-3-3 and Other Brain-specific Proteins in CSF in the Diagnosis of Variant Creutzfeldt-Jakob Disease
JNNP 70:744-748, Green,A.J.E.,et al, 2001
Longitudinal Study of CSF Levels of Tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's Disease
Ann Neurol 44:17-26, 61998., Kanai,M.,et al, 1998
Assessment of CSF Levels of Tau Protein in Mildly Demented Patients with Alzheimer's Disese
Neurol 48:632-635, Galasko,D.,et al, 1997